NasdaqGS:TARSPharmaceuticals
Tarsus Pharmaceuticals (TARS) Is Up 6.1% After Analyst Upgrades Highlight XDEMVY Sales Momentum
In recent days, analysts issued upgrades and initiated positive coverage for Tarsus Pharmaceuticals, highlighting rapid commercialization of XDEMVY, the only approved treatment for Demodex blepharitis.
An important insight is that analyst optimism centers around XDEMVY’s accelerating sales growth and significant untapped patient potential in the U.S. market.
We’ll examine how renewed analyst confidence in XDEMVY’s rollout may influence Tarsus Pharmaceuticals’ growth and earnings outlook...